In this prospective Phase II clinical trial enrolling 80 patients with advanced prostate cancer and pre-existing cardiovascular disease, 41 patients were assigned to Firmagon (an LHRH antagonist) and 39 were assigned to Lupron (an LHRH agonist). During the one year trial period, 20% of the men assigned to Lupron experienced a new major cardiovascular or cerebrovascular event (heart attack or stent or stroke) versus only 3% of the men receiving Firmagon.
You can read the full abstract from the Journal of Urology here: http://tiny.cc/CardioRisk_ADT